The company appointed Gregory Law as chief financial officer (CFO) and Dwayne Montgomery as chief business officer.
Law has been employed with Osiris since 2014 as the vice president of finance and principal accounting officer. Law has more than 25 years of finance and accounting experience in a variety of industries, including biotechnology, telecommunications, energy, private equity and consulting. Prior to joining Osiris in 2014, he spent more than a decade providing consulting services to public and private companies in the areas of interim CFO and controllership, financial reporting, mergers and acquisitions, valuation and compliance. Before his consulting career, Law held a number of finance positions at various public companies, such as XO Communications, MCI and General Electric. He graduated from Virginia Tech with a B.S. in accounting and earned his M.B.A. from George Washington University in Washington, D.C. He also is CPA licensed in Maryland.
Montgomery joined Osiris in April 2014 as general manager for the Orthopaedics and Sports Medicine franchise. In his new role, Montgomery will be responsible for global business development for all products. He will continue to manage the orthopedics and sports medicine businesses and execute the commercial launches of BIO4 and Cartiform with Osiris’ strategic partners Stryker Corp. and Arthrex Inc.
Montgomery brings more than two decades of extensive medical device experience in global commercialization and strategic planning. Prior to joining Osiris, he served as a commercial executive for venture-backed organizations in the trauma and spine markets. These included the role of senior vice president of sales and marketing for IlluminOss Medical as well as vice president commercial operations for Baxano Surgical Inc. Montgomery also held progressing roles of executive responsibility at Smith & Nephew plc, serving as vice president and general manager for the company’s orthopedic and trauma businesses. He also held the role of vice president of sales and marketing for the clinical therapies business, a division that eventually became Bioventus Inc. Montgomery earned a B.S. in chemistry from the University of North Alabama and a M.B.A. from the Massey School of Business at Belmont University in Nashville, Tenn.
Osiris Therapeutics developed the world’s first approved stem cell drug. The company continues to advance its research and development in biotechnology by focusing on innovation in regenerative medicine, including bioengineering, stem cell research and viable tissue based products.